BURLINGAME, CA & HYDERABAD, India, March 27, 2025 – LAXAI, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in small molecules, today announced the appointment of Dr. Susan Billings to its Board of Directors.
“We are pleased to welcome Dr. Billings to the LAXAI Board,” said Vamsi Maddipatla, Managing Director of LAXAI. “Her extensive experience in commercial strategy and business transformation will be invaluable as we strengthen our position as a premier CRDMO. Susan’s leadership in global business development and her deep understanding of the pharmaceutical and biotech landscape will help guide LAXAI’s continued growth and expansion.”
Dr. Billings brings extensive expertise in commercial strategy, business development, and pharmaceutical innovation across both small and large molecules, with a track record of guiding organizations through growth and transformation. As Chief Commercial Officer at Resilience, she leads the commercial function and business development efforts to expand the company’s biomanufacturing capabilities and industry reach. Before joining Resilience, she was the founding Chief Commercial Officer at Vivodyne, a TechBio platform start-up, where she established and led commercial and corporate strategy. Prior to that, she led Curia’s global business development team across drug discovery, development, and manufacturing. With a foundation in scientific and operational roles at an oncology startup and Merck earlier in her career, her combination of technical insight, commercial leadership and strategic vision, make her a valuable addition to LAXAI’s Board as the company advances its position as a leading CRDMO to deliver cutting-edge solutions for pharmaceutical and biotech clients worldwide.
About LAXAI
LAXAI is a US-based Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in small molecule solutions. The company provides comprehensive services to pharmaceutical, biotech, animal health, and specialty chemical industries, with expertise in complex process R&D, seamless project transitions from development to commercial-scale manufacturing, and both GMP and non-GMP production capabilities.
For more information, visit https://laxai.com/